1. Home
  2. OBK vs PHVS Comparison

OBK vs PHVS Comparison

Compare OBK & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Bancorp Inc.

OBK

Origin Bancorp Inc.

HOLD

Current Price

$51.15

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.67

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBK
PHVS
Founded
1912
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
2.3B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
OBK
PHVS
Price
$51.15
$34.67
Analyst Decision
Strong Buy
Buy
Analyst Count
6
11
Target Price
$46.67
$41.82
AVG Volume (30 Days)
131.4K
371.0K
Earning Date
04-22-2026
05-12-2026
Dividend Yield
2.13%
N/A
EPS Growth
N/A
N/A
EPS
0.89
N/A
Revenue
N/A
N/A
Revenue This Year
$26.43
N/A
Revenue Next Year
$5.79
N/A
P/E Ratio
$57.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.13
$17.24
52 Week High
$52.00
$35.33

Technical Indicators

Market Signals
Indicator
OBK
PHVS
Relative Strength Index (RSI) 62.40 64.71
Support Level $48.10 $24.73
Resistance Level N/A N/A
Average True Range (ATR) 1.11 1.63
MACD 0.12 0.20
Stochastic Oscillator 74.10 70.36

Price Performance

Historical Comparison
OBK
PHVS

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: